Ocular Microbiome clinical trials at UC Cancer
1 research study open to eligible people
Showing trials for
Azithromycin for Meibomian Gland Disease
open to eligible people ages 18 years and up
This study aims to elucidate the effectiveness of oral azithromycin in treating symptomatic dry eye syndrome secondary to Meibomian gland dysfunction.
Our lead scientists for Ocular Microbiome research studies include Julie Schallhorn, MD, MS Thuy Doan, MD, PhD.